Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (211-220 of 596) with videos related to

Pageof 60
Sort By:
Blood|October 30, 2010
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Brunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Haematologica|March 17, 2004
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trialAxel Glasmacher, Hartmut Goldschmidt, Jörg Mezger, et al.
British Journal of Haematology|August 6, 2003
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acidMichael Fiegl, Christina Rieger, Jan Braess, et al.
Haematologica|March 23, 2011
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemiaClaudia Haferlach, Ulrike Bacher, Alexander Kohlmann, et al.
Cancer Genetics and Cytogenetics|July 13, 2010
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemiaUlrike Bacher, Torsten Haferlach, Susanne Schnittger, et al.
Blood|July 10, 2009
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AMLSusanne Schnittger, Wolfgang Kern, Claudia Tschulik, et al.
Genes, Chromosomes & Cancer|December 21, 2004
Pattern robustness of diagnostic gene expression signatures in leukemiaAlexander Kohlmann, Claudia Schoch, Martin Dugas, et al.
Leukemia|March 24, 2018
Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patientsAlexander Höllein, Sabine Jeromin, Manja Meggendorfer, et al.
BMC Cancer|June 1, 2006
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragmentsSusanne Mueller, Stefan Holdenrieder, Petra Stieber, et al.
Blood Advances|November 4, 2020
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDSAnna Stengel, Rabia Shahswar, Torsten Haferlach, et al.
Pageof 60

Showing results (211-220 of 596) with videos related to

Sort By:
Pageof 60
Blood|October 30, 2010
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Brunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Haematologica|March 17, 2004
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trialAxel Glasmacher, Hartmut Goldschmidt, Jörg Mezger, et al.
British Journal of Haematology|August 6, 2003
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acidMichael Fiegl, Christina Rieger, Jan Braess, et al.
Haematologica|March 23, 2011
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemiaClaudia Haferlach, Ulrike Bacher, Alexander Kohlmann, et al.
Cancer Genetics and Cytogenetics|July 13, 2010
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemiaUlrike Bacher, Torsten Haferlach, Susanne Schnittger, et al.
Blood|July 10, 2009
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AMLSusanne Schnittger, Wolfgang Kern, Claudia Tschulik, et al.
Genes, Chromosomes & Cancer|December 21, 2004
Pattern robustness of diagnostic gene expression signatures in leukemiaAlexander Kohlmann, Claudia Schoch, Martin Dugas, et al.
Leukemia|March 24, 2018
Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patientsAlexander Höllein, Sabine Jeromin, Manja Meggendorfer, et al.
BMC Cancer|June 1, 2006
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragmentsSusanne Mueller, Stefan Holdenrieder, Petra Stieber, et al.
Blood Advances|November 4, 2020
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDSAnna Stengel, Rabia Shahswar, Torsten Haferlach, et al.
Pageof 60